MCL plans major investment in multiple sclerosis research program
Date: 2018-02-26   Author: Dhananjay Punekar  Category: #news

MCL plans major investment in multiple sclerosis research program

Medical Cannabis Limited (MCL), a division of Queensland Bauxite Limited, has reportedly decided to fund a research program dealing with the deployment of the medical cannabis therapy for multiple sclerosis. It has been speculated that this is the first such initiative taken by MCL to fund any research program on the multiple sclerosis disorder.

As per the agreement between Technion Research & Development Foundation and Medical Cannabis Research Group Private Limited, MCL will promote research & development activities associated with the use of the medical marijuana in treating multiple sclerosis symptoms and stopping the growth of autoimmune diseases. The research is expected to be based on the recognition of synergistic relations between the human genome and the cannabis shrub.

Some of the key executives at the Technion Research & Development Foundation have stated that the main goal of the research program is to recognize particular cannabis compounds, which can find applications in the clinical tests for treating patients with multiple sclerosis. In return for the funding of the research program, which will be carried out under the auspices of Prof. Meiri, MCL will be granted exclusive licensing rights for any product discovered during the research & development activities.

As per the terms & conditions of the deal between the two institutions, Medical Cannabis Research Group (MCRG) will make capital investments worth USD 3 million in the project over the span of three years. In return, MCRG will receive exclusive rights to multiple sclerosis or autoimmune disorder therapies developed via the research project.

Myriad research activities on how medical marijuana can help in treating multiple sclerosis syndrome or autoimmune ailment are now being carried out in several regions across the globe. Experts claim that as on today, the healthcare industry is focusing more on finding cures for incontinence, spasticity, and pain. They also have reason to believe that this strategic move to fund the research on treating multiple sclerosis will promote a further slew of R&D activities to find cures for acute & chronic autoimmune disorders such as multiple sclerosis.



About Author


Dhananjay Punekar

Dhananjay Punekar

Dhananjay currently works as a content writer at AlgosOnline. A post graduate in mathematics as well as business administration, he worked as a process executive in Infosys BPO Limited before switching his professional genre. Following his childhood passion, he opted fo...

Read More

More from Dhananjay


Post Recommendents

Atomwise to collaborate with Hansoh Pharma for AI-based drug discovery
Author: Pankaj Singh

Atomwise Inc., a leading developer of healthcare software that uses AI to discover medicines and agricultural compounds, recently announced that it will be collaborating with Hansoh Pharmaceutical Group Company Limited, a leading Chinese biopharma...


Valsoft acquires Commsoft OASES and enters the aviation vertical
Author: Pankaj Singh

  • Since the company’s first association with airline sector over 40 years ago, Communications Software has been developing the MRO IT system continually.
  • London-based Snyk secures €63Mn from Accel led funding round
    Author: Saipriya Iyer

    The company intends to use this funding to fuel its plans for the next phase of global growth.

    Snyk, a developer-first security company based in London, has repor...